Related references
Note: Only part of the references are listed.Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material
J. S. CROWE et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
High-Dose Cyclophosphamide in the Treatment of Multiple Sclerosis
Robert Jay Schwartzman et al.
CNS NEUROSCIENCE & THERAPEUTICS (2009)
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Young H. Kim et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
O. Stuve et al.
NEUROLOGY (2009)
Cyclophosphamide therapy in pediatric multiple sclerosis
N. Makhani et al.
NEUROLOGY (2009)
Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis
Daniel B. Drachman et al.
MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE (2008)
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis
[Anonymous]
ARCHIVES OF NEUROLOGY (2008)
Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus
Ines C. Kanter et al.
EPILEPSIA (2008)
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety
Valentina Zipoli et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2008)
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
Christine Lebrun et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
R. Zivadinov et al.
NEUROLOGY (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis
Chitra Krishnan et al.
ARCHIVES OF NEUROLOGY (2008)
High dose cyclophosphamide preferentially targets naive T (CD45/CD4/RA+) cells in CIDP and MS patients
Douglas E. Gladstone et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study
L. Roccatagliata et al.
MULTIPLE SCLEROSIS (2007)
Immunosuppression: Promises and failures
Joel Oger
JOURNAL OF THE NEUROLOGICAL SCIENCES (2007)
The safety profile of cyclophosphamide in multiple sclerosis therapy
Paola Perini et al.
EXPERT OPINION ON DRUG SAFETY (2007)
Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database
R. Saccardi et al.
MULTIPLE SCLEROSIS (2006)
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Anne H. Cross et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis
Douglas E. Gladstone et al.
ARCHIVES OF NEUROLOGY (2006)
Emerging monoclonal antibody therapies for multiple sclerosis
Bruce Cree
NEUROLOGIST (2006)
Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis
J. T. Chen et al.
NEUROLOGY (2006)
Immune surveillance in multiple sclerosis patients treated with natalizumab
O Stüve et al.
ANNALS OF NEUROLOGY (2006)
The window of therapeutic opportunity in multiple sclerosis
AJ Coles et al.
JOURNAL OF NEUROLOGY (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta
DR Smith et al.
MULTIPLE SCLEROSIS JOURNAL (2005)
Multiple sclerosis: long-term remission after a high dose of cyclophosphamide
PRM Bittencourt et al.
ACTA NEUROLOGICA SCANDINAVICA (2005)
Treatment of progressive forms of multiple sclerosis by cyclophosphamide:: a cohort study of 490 patients
H Zephir et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2004)
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta
F Patti et al.
JOURNAL OF NEUROLOGY (2004)
Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide
S Takamoto et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2004)
Cyclophosphamide modulates CD4(+) T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8(+) T cells in secondary progressive multiple sclerosis
A Karni et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis
P Perini et al.
JOURNAL OF NEUROLOGY (2003)
Treatment of refractory myasthenia: Rebooting with high-dose cyclophosphamide
DB Drachman et al.
ANNALS OF NEUROLOGY (2003)
Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort
E Portaccio et al.
MULTIPLE SCLEROSIS (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Hematopoietic stem cell transplantation for multiple sclerosis - A retrospective multicenter study
T Kozak et al.
JOURNAL OF NEUROLOGY (2002)
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy
OA Khan et al.
MULTIPLE SCLEROSIS JOURNAL (2001)
Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations
D Meirow et al.
HUMAN REPRODUCTION (2001)
Campath-1H monoclonal antibody therapy
JM Flynn et al.
CURRENT OPINION IN ONCOLOGY (2000)
Share Paper
